Cannabinoids May Slow MS Progression Through Both Immune and Neuroprotective Mechanisms, But Dose Limits Apply | Research

The takeaway

Experimental studies show cannabinoids could modify MS disease progression through CB1-mediated indirect immunosuppression and CB2-mediated direct immune cell inhibition, but clinical dose constraints likely prevent the immunosuppressive benefits from being realized with medical cannabis.

Read this if you have MS and want to understand whether cannabis might slow disease progression, not just manage symptoms.

Immunosuppressive doses of cannabinoids are clinically unfeasible; neuroprotective doses may be achievable

What the researchers found

This review from the British Journal of Pharmacology examined whether cannabinoids can modify the neuroinflammatory process driving MS, beyond just controlling symptoms.

Experimental studies revealed two mechanisms: synthetic cannabinoids can indirectly suppress the immune response through CB1 receptor signaling in nerve centers that control systemic immunosuppression, and can directly inhibit lymphocyte and macrophage/microglial function through CB2 receptors.

However, the review concluded that these immunosuppressive effects, which could reduce relapsing attack frequency, would probably not be achieved clinically through medical cannabis use due to dose constraints: the doses needed for immunosuppression would likely cause unacceptable psychoactive effects.

A more promising avenue was cannabinoid modulation of the glial response within damaged CNS tissue, which could slow the progressive neurodegeneration accounting for disability accumulation in MS.

Why it matters

This review honestly assessed the gap between what cannabinoids can do experimentally and what they can achieve clinically. The distinction between achievable symptom control and unachievable immunosuppression (at tolerable doses) is important for realistic expectations about cannabis-based MS treatments.

The numbers in context

Two mechanisms: CB1-mediated indirect immunosuppression via nerve signaling, CB2-mediated direct immune cell inhibition. Both require doses beyond clinical feasibility. Glial response modulation more promising at tolerable doses.

How the study worked

Review published in the British Journal of Pharmacology examining experimental evidence for cannabinoid effects on neuroinflammation in MS. Covered CB1 and CB2 receptor-mediated mechanisms, clinical dose feasibility, and potential for disease modification versus symptom control.

What this study cannot tell us

Based largely on experimental (animal model) data. The prediction about dose constraints for immunosuppression is theoretical and has not been directly tested in clinical trials. The neuroprotective potential of cannabinoids at clinical doses remains to be proven.

How to read the evidence

Review in a high-impact pharmacology journal. Provides strong mechanistic evidence with realistic clinical assessment. Primarily experimental data.

When this study was published

Published in 2007 in the British Journal of Pharmacology. Research on cannabinoid neuroprotection in MS has continued.

The bigger picture

The concept of disease modification (slowing MS progression) versus symptom control (managing spasticity, pain) is central to MS treatment. This review suggests cannabinoids may contribute to disease modification through neuroprotective glial effects rather than through the immunosuppressive pathway, which would require impractical doses.

Questions still open

Could CB2-selective agonists (without psychoactive effects) achieve immunosuppression at tolerable doses? Can cannabinoid-mediated neuroprotection meaningfully slow MS disability accumulation?

Common questions

Can cannabis slow MS progression?

Experimental evidence suggests cannabinoids could modify MS through both immune suppression and neuroprotection. However, the doses needed for meaningful immunosuppression would cause unacceptable side effects. Neuroprotective effects may be achievable at tolerable doses, but this has not been proven clinically.

Why can't medical cannabis doses achieve immunosuppression?

The immunosuppressive effects of cannabinoids require higher doses than are clinically tolerable. At the doses needed, psychoactive effects and other side effects would be too severe for regular use. This limits medical cannabis to symptom control rather than disease modification through immunosuppression.

Read the original research

Cannabinoid control of neuroinflammation related to multiple sclerosis.

British journal of pharmacology, 152(5), 649-54

View on PubMed ↗

Citation

Baker, D; Jackson, S J; Pryce, G. (2007). Cannabinoid control of neuroinflammation related to multiple sclerosis.. British journal of pharmacology, 152(5), 649-54.